US5662933A
(en)
*
|
1993-09-09 |
1997-09-02 |
Edward Mendell Co., Inc. |
Controlled release formulation (albuterol)
|
US5455046A
(en)
*
|
1993-09-09 |
1995-10-03 |
Edward Mendell Co., Inc. |
Sustained release heterodisperse hydrogel systems for insoluble drugs
|
US5773025A
(en)
|
1993-09-09 |
1998-06-30 |
Edward Mendell Co., Inc. |
Sustained release heterodisperse hydrogel systems--amorphous drugs
|
GB9325445D0
(en)
*
|
1993-12-13 |
1994-02-16 |
Cortecs Ltd |
Pharmaceutical formulations
|
US5567592A
(en)
*
|
1994-02-02 |
1996-10-22 |
Regents Of The University Of California |
Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
|
GB9405304D0
(en)
*
|
1994-03-16 |
1994-04-27 |
Scherer Ltd R P |
Delivery systems for hydrophobic drugs
|
US5430021A
(en)
*
|
1994-03-18 |
1995-07-04 |
Pharmavene, Inc. |
Hydrophobic drug delivery systems
|
DE4443175A1
(de)
*
|
1994-12-05 |
1996-06-13 |
Jenapharm Gmbh |
Neue pulsatile Arzneiform
|
US5834024A
(en)
|
1995-01-05 |
1998-11-10 |
Fh Faulding & Co. Limited |
Controlled absorption diltiazem pharmaceutical formulation
|
ES2154806T3
(es)
*
|
1995-02-06 |
2001-04-16 |
Elan Pharma Int Ltd |
Formulaciones de compuestos como dispersiones de nanoparticulas en aceites o acidos grasos digeribles.
|
US5716928A
(en)
*
|
1995-06-07 |
1998-02-10 |
Avmax, Inc. |
Use of essential oils to increase bioavailability of oral pharmaceutical compounds
|
US5665386A
(en)
*
|
1995-06-07 |
1997-09-09 |
Avmax, Inc. |
Use of essential oils to increase bioavailability of oral pharmaceutical compounds
|
JPH11507356A
(ja)
*
|
1995-06-07 |
1999-06-29 |
アブマックス,インコーポレイティド |
経口薬理化合物の生物有用性を高めるためのエッセンシャルオイルの利用
|
US6024980A
(en)
*
|
1996-06-28 |
2000-02-15 |
Mcneil-Ppc, Inc. |
Multiphase soft gelatin dosage form
|
WO1998001117A1
(en)
|
1996-07-08 |
1998-01-15 |
Edward Mendell Co., Inc. |
Sustained release matrix for high-dose insoluble drugs
|
US6458373B1
(en)
*
|
1997-01-07 |
2002-10-01 |
Sonus Pharmaceuticals, Inc. |
Emulsion vehicle for poorly soluble drugs
|
US6056977A
(en)
*
|
1997-10-15 |
2000-05-02 |
Edward Mendell Co., Inc. |
Once-a-day controlled release sulfonylurea formulation
|
US20030008919A1
(en)
*
|
1999-06-03 |
2003-01-09 |
Jean-Baptiste Roullet |
Use of retinoids to treat high blood pressure and other cardiovascular disease
|
JP2002500190A
(ja)
|
1998-01-08 |
2002-01-08 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
海洋海綿から誘導されるキネシンモーターモジュレーター
|
US7030155B2
(en)
*
|
1998-06-05 |
2006-04-18 |
Sonus Pharmaceuticals, Inc. |
Emulsion vehicle for poorly soluble drugs
|
US6524620B2
(en)
|
1998-07-20 |
2003-02-25 |
Andrx Pharmaceuticals, Inc. |
Diltiazem controlled release formulation and method of manufacture
|
US6200968B1
(en)
*
|
1998-08-06 |
2001-03-13 |
Cephalon, Inc. |
Particle-forming compositions containing fused pyrrolocarbazoles
|
FR2782006B1
(fr)
*
|
1998-08-07 |
2002-04-19 |
Gattefosse Ets Sa |
Composition a liberation prolongee apte a former une micro-emulsion
|
PL348193A1
(en)
|
1998-12-11 |
2002-05-06 |
Pharmasolutions |
Self-emulsifying compositions for drugs poorly soluble in water
|
US6057289A
(en)
*
|
1999-04-30 |
2000-05-02 |
Pharmasolutions, Inc. |
Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
|
CA2409437A1
(en)
*
|
2000-05-11 |
2001-11-22 |
Pharmacia Corporation |
Aldosterone antagonist composition for release during aldosterone acrophase
|
US6664230B1
(en)
|
2000-08-24 |
2003-12-16 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
US8568766B2
(en)
*
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
CA2480826C
(fr)
*
|
2002-04-09 |
2012-02-07 |
Flamel Technologies |
Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
|
US7670612B2
(en)
|
2002-04-10 |
2010-03-02 |
Innercap Technologies, Inc. |
Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
|
US20040005359A1
(en)
*
|
2002-06-27 |
2004-01-08 |
Cheng Xiu Xiu |
Controlled release oral dosage form
|
US20040077621A1
(en)
*
|
2002-08-08 |
2004-04-22 |
Academia Sinica |
Antioxidants
|
CA2515544A1
(en)
*
|
2003-02-11 |
2004-08-26 |
Kemia Inc. |
Compounds for the treatment of viral infection
|
US7314640B2
(en)
*
|
2003-07-11 |
2008-01-01 |
Mongkol Sriwongjanya |
Formulation and process for drug loaded cores
|
KR20060123551A
(ko)
*
|
2004-01-14 |
2006-12-01 |
라비팜 라보라토리즈, 인크. |
최소한 한 개의 지방산을 포함하는 디하이드로피리딘 타입칼슘 길항제용 경피 전달 장치
|
MXPA06009054A
(es)
*
|
2004-02-11 |
2007-04-16 |
Athpharma Ltd |
Composiciones cronoterapeuticas y metodos de su uso.
|
US8741635B2
(en)
|
2004-05-12 |
2014-06-03 |
The Walter And Eliza Hall Institute Of Medical Research |
Method of cell isolation
|
WO2006095347A2
(en)
|
2005-03-10 |
2006-09-14 |
Ben Gurion University Of The Negev Research And Development Authority Ltd. |
VOLTAGE DEPENDENT ANION CHANNEL (VDACl) COMPOSITIONS AND METHODS OF USE THEREOF FOR REGULATING APOPTOSIS
|
US8648045B2
(en)
|
2005-03-10 |
2014-02-11 |
Ben Gurion University Of The Negev Research And Development Authority Ltd. |
VDAC1 compositions and methods of use thereof for regulating apoptosis
|
EP1890715A4
(en)
|
2005-04-29 |
2009-10-28 |
Univ California |
PEPTIDES AND PEPTIDE MIMETICS FOR TREATMENT BY INFLAMMATORY REACTION OF CHARACTERIZED PATHOLOGIES
|
WO2006135985A1
(en)
|
2005-06-24 |
2006-12-28 |
The Walter And Eliza Hall Institute Of Medical Research |
Therapeutic pro-apoptotic bh3-like molecules and methods for generating and/or selecting the same
|
US8691272B2
(en)
*
|
2005-12-30 |
2014-04-08 |
Intelgenx Corp. |
Multilayer tablet
|
AU2007207341B2
(en)
|
2006-01-20 |
2012-05-10 |
Women's & Children's Health Research Institute Incorporated |
Method of treatment, prophylaxis and diagnosis of pathologies of the bone
|
US8440788B2
(en)
*
|
2006-04-06 |
2013-05-14 |
Ben-Gurion University Of The Negev Research And Development Authority Ltd. |
N-terminal VDAC variants and uses thereof
|
WO2007123153A1
(ja)
*
|
2006-04-19 |
2007-11-01 |
Ono Pharmaceutical Co., Ltd. |
経口投与用カプセル
|
MY153288A
(en)
*
|
2006-06-28 |
2015-01-29 |
Hovid Berhad |
An effective pharmaceutical carrier for poorly bioavailable drugs
|
KR101390695B1
(ko)
*
|
2006-08-01 |
2014-04-30 |
오츠카 세이야쿠 가부시키가이샤 |
약리 활성 물질의 흡수성이 개선된 의약 조성물
|
EP2086512A2
(en)
*
|
2006-10-27 |
2009-08-12 |
Janssen Pharmaceutica N.V. |
Dry granulated pharmaceutical compositions and methods for producing same
|
CA2691539C
(en)
*
|
2007-06-21 |
2014-08-26 |
Angelica Therapeutics, Inc. |
Modified toxins
|
ES2402334T3
(es)
|
2007-08-02 |
2013-04-30 |
Gilead Biologics, Inc |
Procedimientos y composiciones para el tratamiento y el diagnóstico de la fibrosis
|
WO2009032693A2
(en)
*
|
2007-08-28 |
2009-03-12 |
Uab Research Foundation |
Synthetic apolipoprotein e mimicking polypeptides and methods of use
|
US8557767B2
(en)
|
2007-08-28 |
2013-10-15 |
Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
EP2205245B1
(en)
*
|
2007-10-03 |
2015-06-24 |
WisTa Laboratories Ltd. |
Therapeutic use of diaminophenothiazines
|
WO2009110944A1
(en)
|
2008-02-29 |
2009-09-11 |
Angelica Therapeutics, Inc. |
Modified toxins
|
ES2390562T3
(es)
*
|
2008-05-12 |
2012-11-14 |
Capsugel Belgium Nv |
Cápsula mejorada con aberturas para el aire
|
US20100082438A1
(en)
*
|
2008-10-01 |
2010-04-01 |
Ronnie Jack Garmon |
Methods and systems for customer performance scoring
|
US9050276B2
(en)
|
2009-06-16 |
2015-06-09 |
The Trustees Of Columbia University In The City Of New York |
Autism-associated biomarkers and uses thereof
|
EP2722055A1
(en)
|
2009-08-17 |
2014-04-23 |
Tracon Pharmaceuticals, Inc. |
Combination therapy with antibodies and anti-VEGF agents for the treatment of cancer
|
US8221753B2
(en)
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
ES2363965B1
(es)
*
|
2009-11-20 |
2013-01-24 |
Gp Pharm S.A. |
Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
|
US10610528B2
(en)
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
US20110136815A1
(en)
*
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
US9249189B2
(en)
|
2010-01-18 |
2016-02-02 |
Albany Medical College |
Alpha-fetoprotein “ring and tail” peptides
|
PL2608809T3
(pl)
|
2010-08-27 |
2019-10-31 |
Gilead Biologics Inc |
Przeciwciała dla metaloproteinazy 9 macierzy
|
CN108404115A
(zh)
|
2010-10-15 |
2018-08-17 |
纽约市哥伦比亚大学理事会 |
肥胖症-相关的基因和它们的蛋白和其用途
|
AU2012249301A1
(en)
|
2011-04-29 |
2013-11-21 |
Kinemed, Inc. |
Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents
|
CN103957888B
(zh)
*
|
2011-09-29 |
2017-11-21 |
PLx 制药公司 |
用于将药物沿胃肠道靶向释放的pH依赖性载体、其组合物及其制备和应用
|
US9550836B2
(en)
|
2012-02-29 |
2017-01-24 |
Gilead Biologics, Inc. |
Method of detecting human matrix metalloproteinase 9 using antibodies
|
CN104271156B
(zh)
|
2012-02-29 |
2017-06-16 |
吉利德生物制剂公司 |
抗基质金属蛋白酶9的抗体
|
US20150011471A1
(en)
|
2012-03-01 |
2015-01-08 |
Yeda Research And Development Co. Ltd. |
Regeneration of islet beta cells by hsp60 derived peptides
|
US10039777B2
(en)
|
2012-03-20 |
2018-08-07 |
Neuro-Lm Sas |
Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
|
TW201406707A
(zh)
|
2012-05-04 |
2014-02-16 |
Acucela Inc |
用以治療糖尿病性視網膜病變及其他眼部疾病之方法
|
EP2874647B1
(en)
|
2012-07-20 |
2018-10-24 |
La Trobe University |
Method of diagnosis and treatment of metastatic cancer
|
UA115789C2
(uk)
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
NZ713291A
(en)
|
2013-03-14 |
2017-04-28 |
Uab Res Found |
Apolipoprotein mimetics and uses thereof
|
CA2902905A1
(en)
|
2013-03-15 |
2014-09-25 |
Claude Geoffrey Davis |
Modified toxins
|
EP2968503B1
(en)
|
2013-03-15 |
2018-08-15 |
Intrinsic LifeSciences LLC |
Anti-hepcidin antibodies and uses thereof
|
CA2902209A1
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California |
Peptides having reduced toxicity that stimulate cholesterol efflux
|
US9758559B2
(en)
|
2013-07-25 |
2017-09-12 |
B.G. Negev Technologies And Applications Ltd., At Ben-Gurion University |
Short peptides derived from VDAC1, compositions and methods of use thereof
|
US9873724B2
(en)
|
2013-12-20 |
2018-01-23 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Pro-angiogenic peptides and peptide conjugates
|
CA2940869A1
(en)
|
2014-02-27 |
2015-09-03 |
Gilead Sciences, Inc. |
Antibodies to matrix metalloproteinase 9 and methods of use thereof
|
US20150361182A1
(en)
|
2014-06-11 |
2015-12-17 |
Gilead Sciences, Inc. |
Methods for treating cardiovascular diseases
|
US10155790B2
(en)
|
2014-07-17 |
2018-12-18 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antagonists of neurokinin B in fish reproduction
|
US10793614B2
(en)
|
2014-07-17 |
2020-10-06 |
Yissum Research Development Company of the Hebrew University ofJerusaIem Ltd. |
Antagonists of fish reproduction
|
WO2016019333A1
(en)
|
2014-07-31 |
2016-02-04 |
Kinemed, Inc. |
The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
|
EP3189069B1
(en)
|
2014-07-31 |
2024-10-23 |
UAB Research Foundation |
Apoe mimetic peptides and higher potency to clear plasma cholesterol
|
CA2961917A1
(en)
|
2014-09-22 |
2016-03-31 |
Intrinsic Lifesciences Llc |
Humanized anti-hepcidin antibodies and uses thereof
|
US9926375B2
(en)
|
2014-11-12 |
2018-03-27 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
AU2015346444A1
(en)
|
2014-11-12 |
2017-05-04 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
AU2016315873B2
(en)
|
2015-09-04 |
2022-08-18 |
Primatope Therapeutics Inc. |
Humanized anti-CD40 antibodies and uses thereof
|
US10149887B2
(en)
|
2015-10-23 |
2018-12-11 |
Canbas Co., Ltd. |
Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
|
JP6877419B2
(ja)
|
2015-10-27 |
2021-05-26 |
ザ ユニバーシティー オブ クイーンズランド |
治療の方法およびそのために有用な剤
|
WO2017083700A1
(en)
|
2015-11-13 |
2017-05-18 |
The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas |
Ligand-guided phagocytosis based therapy for treatment of alzheimer's disease and other neurodegenerative diseases
|
US20170174788A1
(en)
|
2015-12-17 |
2017-06-22 |
Gilead Sciences, Inc. |
Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
|
CA3019003A1
(en)
|
2016-04-08 |
2017-10-12 |
Gilead Sciences, Inc. |
Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
|
WO2018071814A1
(en)
|
2016-10-14 |
2018-04-19 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating alcohol abuse disorder
|
EP3574003A4
(en)
|
2017-01-30 |
2020-12-02 |
Hudson Institute of Medical Research |
TREATMENT PROCEDURES
|
WO2018213803A1
(en)
|
2017-05-19 |
2018-11-22 |
Neon Therapeutics, Inc. |
Immunogenic neoantigen identification
|
JP7366755B2
(ja)
|
2017-05-30 |
2023-10-23 |
ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ オクラホマ |
抗ダブルコルチン様キナーゼ1抗体および使用方法
|
KR102484433B1
(ko)
|
2017-11-08 |
2023-01-03 |
바이오엔테크 유에스 인크. |
T 세포 제조 조성물 및 방법
|
WO2020252208A2
(en)
|
2019-06-11 |
2020-12-17 |
Myeloid Therapeutics, Inc. |
Macrophage specific engager compositions and methods of use thereof
|
BR112021025050A2
(pt)
|
2019-06-12 |
2022-05-03 |
Biontech Us Inc |
Composições de neoantígeno e usos das mesmas
|
CA3172595A1
(en)
|
2020-03-26 |
2021-09-30 |
Ronald Zimmerman |
Pharmaceutical carriers capable of ph dependent reconstitution and methods for making and using same
|
BR112023002733A2
(pt)
|
2020-08-13 |
2023-05-02 |
Biontech Us Inc |
Composições e métodos de fabricação de células t
|
JP2023549140A
(ja)
|
2020-11-04 |
2023-11-22 |
マイエロイド・セラピューティクス,インコーポレーテッド |
操作されたキメラ融合タンパク質組成物およびその使用方法
|